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Aims Men and women differ in terms of presentation and management in coronary artery disease (CAD). Whether these
differences translate into different clinical outcomes in stable CAD is unclear. We analysed data from the internation-
al prospective CLARIFY registry to compare cardiovascular clinical outcomes in men and women with stable CAD.
Methods
and results
We analysed 1-year outcomes in 30 977 outpatients with stable CAD [23 975 (77.4%) men; 7002 (22.6%) women].
Women were older than men, more likely to have hypertension and diabetes, and less likely to exercise or smoke.
They had more frequent angina, but were less likely to have undergone diagnostic non-invasive testing or coronary
angiography. Women received less optimized treatment for stable CAD. One-year outcomes were similar for men
and women for the composite of cardiovascular death, non-fatal myocardial infarction, or stroke [adjusted rates 1.7
vs. 1.8%, respectively, odds ratio (OR) 0.93, 95% confidence interval (CI) 0.75–1.15]; all-cause death (adjusted 1.5 vs.
1.6%, OR: 0.91, 95% CI: 0.72–1.13); fatal or non-fatal myocardial infarction (adjusted 1.0 vs. 0.9%, OR: 0.81, 95 CI:
0.60–1.08); and cardiovascular death or non-fatal myocardial infarction (adjusted 1.4 vs. 1.4%, OR: 0.89, 95% CI:
0.70–1.12). Fewer women underwent revascularization (2.6 vs. 2.2%, OR: 0.77, 95% CI: 0.64–0.93), although appro-
priateness was not analysed.
Conclusion The risk profiles of women and men with stable CAD differ substantially. However, 1-year outcomes were similar.
Fewer women underwent revascularization. Further research is needed to better understand gender determinants of
outcome and devise strategies to minimize bias in the management and treatment of women.
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Introduction
Within cardiovascular diseases, coronary artery disease (CAD) is
the single most frequent cause of death in both sexes and is
responsible for more than half of all cardiovascular events.1,2
There are differences between men and women in terms of pres-
entation and management in all forms of CAD: stable angina or
acute coronary syndromes (ACS).3,4 Women with CAD are on
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average older than men, with higher rates of cardiovascular risk
factors; they are also less likely to receive optimized medical treat-
ment or revascularization for their condition.5– 9 Whether these
gender differences translate into a different prognosis is unclear.
While some reports found gender differences in outcomes for
stable angina or ACS,6,9,10 others did not.11– 14 Furthermore,
most contemporary studies of CAD patients are limited to a
single country or specific geographical region, or a particular mani-
festation of disease [e.g. angina symptoms or acute myocardial in-
farction (MI)].6,15– 20
CLARIFY (ProspeCtive observational LongitudinAl RegIstry oF
patients with stable coronary arterY disease) is an ongoing inter-
national prospective observational longitudinal registry in
.33 000 patients with stable CAD in 45 countries.21,22 Women
make up nearly a quarter of the CLARIFY population.21 We set
out to use the CLARIFY database to explore differences in out-
comes between men and women treated for stable CAD, in par-
ticular in patients post-MI or post-revascularization.
Methods
Study design and patients
CLARIFY is an ongoing prospective, international, observational, and
longitudinal registry in 33 285 outpatients with stable CAD receiving
standard management. The rationale, design, and baseline characteris-
tics of CLARIFY have been described elsewhere21,22 (further informa-
tion can also be found online at www.clarify-registry.com). Patients
were enrolled in 45 countries in Africa, Asia, Australia, Europe, the
Middle East, and North, Central, and South America. A detailed list
of countries, sites, and investigators is available from Steg et al.21
Patients are being treated according to usual clinical practice at each
institution, with no specific tests or therapies defined in the study
protocol. The 2898 participating physicians were selected on the
basis of geographic distribution; each was requested to recruit 10–
15 consecutive stable CAD outpatients to meet a predefined
country target of 25 patients per million inhabitants (range 12.5–50)
and obtain an epidemiologically representative population in each
country. Eligible patients had stable CAD defined as at least one of
the following: documented MI .3 months before enrolment; angio-
graphic demonstration of coronary stenosis .50%; chest pain with evi-
dence of myocardial ischaemia (stress electrocardiogram); or coronary
artery bypass graft (CABG) or percutaneous coronary intervention
(PCI) .3 months before enrolment. These criteria were not mutually
exclusive. Exclusion criteria were hospital admission for cardiovascular
reasons (including revascularization) in the past 3 months, planned
revascularization, or conditions hampering the participation or the
5-year follow-up (such as limited cooperation, limited legal capacity,
serious non-cardiovascular disease or conditions interfering with life
expectancy (e.g. cancer, drug abuse) or severe other cardiovascular
disease (e.g. advanced heart failure, severe valve disease, history of
valve repair/replacement). To ensure that the study population was
representative of stable CAD outpatients, recruitment of sites and sub-
jects was based on predefined selection of physicians (cardiologists, as
well as office-based primary care physicians and physicians based in
hospitals with outpatient clinics) by national coordinators, using the
best available epidemiological data in each country reflecting the
burden of CAD, to provide a distribution of physicians across
regions and locations (i.e. urban, suburban, or rural areas) mimicking
the epidemiological patterns in each country. In each practice,
patient enrolment was restricted over a brief period to achieve near
consecutive patient enrolment. The first patient was included on 26
November 2009 and recruitment was completed on 30 June 2010.
The study is in accordance with the principles in the Declaration of
Helsinki and local ethical approval was obtained in all countries prior
to recruitment. All patients gave written informed consent. The
study is registered (ISRCTN43070564).
Data collection
The investigators completed standardized electronic case report forms
(eCRFs) at baseline and at an actual patient visit 1-year+3 months
after enrolment. For patients missing the 1-year visit, telephone
contact with the patient, a designated relative or contact, or his/her
physician was attempted. Where applicable, registries could be used
to retrieve the vital status. A number of measures were implemented
to ensure data quality, including onsite monitoring visits of 100% of the
data in 5% of centres selected at random; regular telephone contact
with investigators to limit missing data and loss to follow-up; and cen-
tralized verification of the eCRF for completeness, consistency, and ac-
curacy. At baseline and follow-up, data were collected on
demographics, risk factors and lifestyle, medical history, physical condi-
tion and vital signs, current symptoms, and current treatments. Avail-
able results of invasive and non-invasive tests were collected, but no
test was mandated by the study and there was no standardized meas-
urement of the left ventricular ejection fraction. At the 1-year visit,
clinical outcomes occurring over the year were recorded. We analysed
the CLARIFY population by gender and compared the rates of the fol-
lowing outcomes in men and women at 1 year: all-cause death; fatal or
non-fatal MI; cardiovascular death; or non-fatal MI; a combined end-
point of cardiovascular death, non-fatal MI, or non-fatal stroke; all cor-
onary events [fatal or non-fatal MI, revascularization (PCI or CABG),
or unstable angina]; and revascularization (PCI or CABG). For the
purpose of this analysis, we defined the main outcome as the compos-
ite of cardiovascular death, MI, and stroke, as these events are object-
ively defined and are less likely to be affected by gender differences in
ascertainment or management than coronary events, which include
myocardial revascularization. As sensitivity analyses, we also examined
these clinical outcomes in two patient subsets of interest, expected to
represent more severe disease: patients with angiographic evidence of
CAD (defined as .50% stenosis in at least one vessel) and patients
with a history of MI or revascularization. For all composite outcomes,
we analysed the number of patients with at least one event from the
combination outcomes. Patients experiencing more than one contrib-
uting event were counted only once. There was no time to event ana-
lysis. Events were accepted as reported by physicians and were not
adjudicated. However, all events were source-verified during the
audits, which were performed at 5% of randomly selected sites.
Statistical analysis
Baseline characteristics for the whole population and by gender are
presented using descriptive statistics with mean (SD) or median [Q1,
Q3] for continuous variables, depending on the distribution of the
data, and numbers (%) for categorical variables. Baseline values were
compared between men and women using Student’s t-test or the
Kruskal–Wallis test for continuous variables, again depending on
the distribution of the data, and x2 tests for categorical variables.
The risk of outcomes was compared between men and women
using a logistic regression analysis to produce odds ratios (ORs) and
corresponding 95% confidence intervals (CIs) adjusted for baseline dif-
ferences (age, presence and severity of angina, diabetes, hypertension,
MI history, peripheral artery disease, heart rate, and systolic blood
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pressure). Statistical analysis was performed at the Robertson Centre
for Biostatistics at the University of Glasgow, UK, using the SAS
(version 9.2) statistical program.
Results
A total of 33 284 patients were included at baseline,21 and gender
was recorded on the eCRF for 33 221 (99.8%). The flow of patient
from enrolment to 1-year analysis is depicted in Figure 1. Of these,
118 patients (0.4%) withdrew consent before 1 year and 924
patients (2.8%) were lost to follow-up. Finally, at the time of this
analysis, follow-up was ongoing and data were incomplete in
1202 (3.6%) patients. These patients were not included in the
present analyses. Complete outcomes were collected and available
for 30 977 patients (93.2%) who completed a 1-year follow-up or
died before the annual visit. There were 23 975 (77.4%) men and
7002 (22.6%) women. Major baseline characteristics were com-
pared between patients with and without follow-up in Supplemen-
tary material online, Table S1 and show important differences in
baseline characteristics, which are associated with similarly import-
ant differences in geographic distribution.
At baseline, the CLARIFY women were older than their male
counterparts [66.5 (9.9) vs. 63.4 (10.5) years] and were more
likely to have diabetes (32.7 vs. 28.0%) and treated hypertension
(78.5 vs. 68.9%); they were more likely to have no physical activity
(22.6 vs. 13.9%) and were less likely to smoke (7.2 vs. 14.1%)
(Table 1). With regard to disease characteristics and medical
history, women had a slightly higher heart rate (palpation) [69.6
(10.5) vs. 67.9 (10.6) b.p.m.] and systolic blood pressure [133.3
(17.5) vs. 130.4 (16.3) mmHg]; they also had slightly higher left ven-
tricular ejection fraction than men [58.0 (10.6) vs. 55.6% (11.1%)].
Women had lower rates than men of previous MI (51.1 vs.
62.1%), previous PCI (54.8 vs. 59.5%), and previous CABG (17.5
vs. 25.1%). More women than men had anginal symptoms (28.6
vs. 20.9% in men), and the symptoms were more severe, as deter-
mined by the Canadian Cardiovascular Society Class. Women also
had more frequent and severe symptoms of heart failure, as mea-
sured by New York Heart Association functional class.
Figure 1 Patient flow from enrolment to 1-year analysis.
Women and men with stable coronary artery disease 2833
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Table 1 Baseline characteristics
Parameter (no. of patients with data available) Total (n 5 30 977) Men (n5 23 975) Women (n5 7002) P-valuea
Demographic characteristic
Age, years (n ¼ 30 977) 64.1 (10.5) 63.4 (10.5) 66.5 (9.9) ,0.0001
Body mass index, kg/m2 (n ¼ 30 949) 27.3 (24.8, 30.4) 27.3 (24.9, 30.1) 27.3 (24.2, 31.1) 0.87
Ethnicity (n ¼ 30 977)
Caucasian 20 458 (66.0) 15 825 (66.0) 4633 (66.2) ,0.0001
South Asian 2462 (7.9) 1945 (8.1) 517 (7.4)
Chinese 2618 (8.5) 1999 (8.3) 619 (8.8)
Japanese/Korean 1024 (3.3) 758 (3.2) 266 (3.8)
Hispanic 1352 (4.4) 993 (4.1) 359 (5.1)
Black/African 301 (1.0) 208 (0.9) 93 (1.3)
Unknown 2762 (8.9) 2247 (9.4) 515 (7.4)
Cardiovascular risk factors
Smoking status (n ¼ 30 972)
Current 3870 (12.5) 3368 (14.1) 502 (7.2) ,0.0001
Former 14 139 (45.7) 12 713 (53.0) 1426 (20.4)
Never 12 963 (41.9) 7890 (32.9) 5073 (72.5)
Dyslipidaemiab (n ¼ 30 974) 23 179 (74.8) 17 940 (74.8) 5239 (74.8) 0.98
Treated hypertension (n ¼ 30 974) 22 023 (71.1) 16 525 (68.9) 5498 (78.5) ,0.0001
Family history of premature CADc (n ¼ 30 970) 8833 (28.5) 6661 (27.8) 2172 (31.0) ,0.0001
Diabetesd (n ¼ 30 973) 8995 (29.0) 6705 (28.0) 2290 (32.7) ,0.0001
Physical activity (n ¼ 30 972)
None 4916 (15.9) 3331 (13.9) 1585 (22.6) ,0.0001
Light physical activity most weeks 16 056 (51.8) 12 161 (50.7) 3895 (55.7)
.20 min physical activity once or twice weekly 5167 (16.7) 4329 (18.1) 838 (12.0)
.20 min physical activity .3 times weekly 4833 (15.6) 4152 (17.3) 681 (9.7)
Medical history
Time since diagnosis of CAD, years (n ¼ 30 975) 5 (2, 9) 5 (2, 10) 4 (2, 8) ,0.0001
Myocardial infarction (n ¼ 30 976) 18 464 (59.6) 14 883 (62.1) 3581 (51.1) ,0.0001
Coronary angiography performed (n ¼ 30 977) 26 320 (85.0) 20 747 (86.5) 5573 (79.6) ,0.0001
Non-invasive test for myocardial ischaemia (n ¼ 30 969) 19 066 (61.6) 15 003 (62.6) 4063 (58.1) ,0.0001
Evidence for myocardial ischaemia (n ¼ 30 970) 5082 (16.4) 3851 (16.1) 1231 (17.6) 0.0025
Percutaneous coronary intervention (n ¼ 30 975) 18 101 (58.4) 14 261 (59.5) 3840 (54.8) ,0.0001
Coronary artery bypass graft (n ¼ 30 974) 7246 (23.4) 6023 (25.1) 1223 (17.5) ,0.0001
Peripheral arterial disease (n ¼ 30 972) 3012 (9.7) 2418 (10.1) 594 (8.5) ,0.0001
Asthma/COPD (n ¼ 30 975) 2276 (7.3) 1677 (7.0) 599 (8.6) ,0.0001
Hospital admission for heart failure (n ¼ 30 976) 1434 (4.6) 1072 (4.5) 362 (5.2) 0.014
Stroke (n ¼ 30 976) 1231 (4.0) 936 (3.9) 295 (4.2) 0.24
Transient ischaemic attack (n ¼ 30 975) 962 (3.1) 707 (2.9) 255 (3.6) 0.0033
Symptomatic status
Angina (n ¼ 30 977) 7007 (22.6) 5002 (20.9) 2005 (28.6) ,0.0001
CCS class (if angina) (n ¼ 7003)
I 1992 (28.4) 1483 (29.7) 509 (25.4) 0.0018
II 3727 (53.2) 2634 (52.7) 1093 (54.5)
III 1209 (17.3) 833 (16.7) 376 (18.8)
IV 75 (1.1) 49 (1.0) 26 (1.3)
Continued
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At baseline, women were less likely than men to have undergone
coronary angiography (79.6 vs. 86.5%, P, 0.0001) or non-invasive
testing for myocardial ischaemia (58.1 vs. 62.6%, P, 0.0001) at any
time. Among patients with angiographic data, the extent of CAD
was less in women with more men having multivessel disease than
women and, conversely, more women with single vessel disease
than men. Likewise, more women had no evidence of angiographic
stenosis .50% in at least one vessel than men. The presence of myo-
cardial ischaemia on non-invasive testing was higher in women.
At baseline, the use of evidence-based drugs for prevention in
CAD was high in the CLARIFY population. A large majority of
patients from both sexes were receiving lipid-lowering agents
(92.2%) and aspirin (87.7%), and three-quarters were receiving
angiotensin-converting enzyme inhibitors or angiotensin II recep-
tor blockers (76.0%) and beta-blockers (75.2%) (Table 2). There
were few differences between the treatments received by men
and women at baseline, although women in CLARIFY were slightly
less likely to be receiving lipid-lowering agents (90.1 vs. 92.9%),
aspirin (87.0 vs. 87.9%), and thienopyridines (25.3 vs. 26.8%), and
more likely to be treated with all categories of antianginal agents
(except beta-blockers), than men, and were more likely to be re-
ceiving diuretics (37.7 vs. 26.9%).
Overall, at the 1-year follow up, there were 1794 coronary
events and 529 patients experienced either cardiovascular death,
non-fatal MI, or non-fatal stroke. Unadjusted outcome event
rates were very similar between men and women (Figure 2).
After adjustment for baseline differences, event rates were
similar for men and women for the composite outcome of cardio-
vascular death, non-fatal MI, or non-fatal stroke [407 (1.7%) vs. 122
(1.8%), OR: 0.93, 95% CI: 0.75–1.15, P ¼ 0.50]. Likewise, there was
no difference in clinical event rates for all-cause death (P ¼ 0.39),
fatal or non-fatal MI (P ¼ 0.15), cardiovascular death or non-fatal
MI (P ¼ 0.33), unstable angina (P ¼ 0.23), and the composite of
all coronary events (P ¼ 0.67) (Figure 2). These results were homo-
geneous across geographic regions (see Supplementary material
online, Table S2). Conversely, fewer women than men underwent
myocardial revascularization (PCI or CABG) (P ¼ 0.007), driven
largely by patients from Western and Eastern Europe.
Sensitivity analyses were performed to assess outcomes in
selected patient subsets (Table 3). First, we analysed patients
with angiographic evidence of CAD (with stenosis .50% in at
least one vessel) (n ¼ 25 314) and found no interaction between
outcomes by gender and presence and the extent of angiographic
evidence of CAD (data not shown). The results were therefore
consistent with those from the overall analysis (Table 3). Then,
we studied patients with either a history of MI or of previous revas-
cularization (n ¼ 28 026). In that subset, results were also consist-
ent with the overall analysis. However, there was a statistically
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Table 1 Continued
Parameter (no. of patients with data available) Total (n5 30 977) Men (n5 23 975) Women (n5 7002) P-valuea
Heart failure symptoms (NYHA class) (n ¼ 30 977)
No heart failure 26 242 (84.7) 20 497 (85.5) 5745 (82.0) ,0.0001
Class II 3964 (12.8) 2922 (12.2) 1042 (14.9)
Class III 771 (2.5) 556 (2.3) 215 (3.1)
Angiographic findings (n ¼ 26 282)
No diseased vessel 968 (3.7) 610 (2.9) 358 (6.4) ,0.0001
One-vessel disease 10 815 (41.1) 8239 (39.8) 2576 (46.3)
Two or more vessel disease 14 499 (55.2) 11 868 (57.3) 2631 (47.3)
Cardiac parameters
Heart rate (palpation), b.p.m. (n ¼ 30 963) 68.3 (10.6) 67.9 (10.6) 69.6 (10.5) ,0.0001
Heart rate (electrocardiography), b.p.m. (n ¼ 23 034) 67.2 (11.4) 66.7 (11.4) 69.0 (11.5) ,0.0001
Systolic blood pressure, mmHg (n ¼ 30 969) 131.0 (16.7) 130.4 (16.3) 133.3 (17.5) ,0.0001
Diastolic blood pressure, mmHg (n ¼ 30 969) 77.3 (10.0) 77.3 (9.9) 77.0 (10.4) 0.0042
Left ventricular ejection fraction, % (n ¼ 21 283) 56.1 (11.0) 55.6 (11.1) 58.0 (10.6) ,0.0001
Electrocardiography rhythm (n ¼ 23 020)
Sinus rhythm 21 888 (95.1) 16 974 (94.9) 4914 (95.6) 0.10
Atrial fibrillation/flutter 772 (3.4) 614 (3.4) 158 (3.1)
Paced rhythm 360 (1.6) 293 (1.6) 67 (1.3)
CCS, Canadian Cardiovascular Society; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association.
Values are numbers (percentages), means (SD), or medians [Q1, Q3].
aMen vs. women.
bDefined as a history of documented total cholesterol .2 g/L (5.18 mmol/L) or high-density lipoprotein cholesterol ,0.4 g/L or ,1 mmol/L.
cDefined as myocardial infarction, sudden death, or stable angina at age ,55 years (men) and ,65 years (women) in a first-degree relative.
dRefers to a history of diabetes or current diabetes (diagnosed by two fasting blood glucose measures .7 mmol/L or 126 mg/L, or abnormal oral glucose tolerance test) treated
or not.
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Table 2 Treatments at baseline
Treatment (no. of patients with data available) Whole population (n 5 30 977) Men (n 5 23 975) Women (n 5 7002) P-valuea
Lipid-lowering drug (n ¼ 30 972) 28 566 (92.2) 22 262 (92.9) 6304 (90.1) ,0.0001
Statins (n ¼ 30 972) 25 638 (82.8) 20 027 (83.5) 5611 (80.2) ,0.0001
Aspirin (n ¼ 30 971) 27 165 (87.7) 21 073 (87.9) 6092 (87.0) 0.048
Thienopyridine (n ¼ 30 957) 8201 (26.5) 6431 (26.8) 1770 (25.3) 0.01
Other antiplatelet agent (n ¼ 30 957) 2868 (9.3) 2208 (9.2) 660 (9.4) 0.59
Oral anticoagulant agent (n ¼ 30 970) 2548 (8.2) 2055 (8.6) 493 (7.0) ,0.0001
ACE inhibitor and/or ARB (n ¼ 30 969) 23 543 (76.0) 18 203 (75.9) 5340 (76.3) 0.54
Beta-blocker (n ¼ 30 972) 23 299 (75.2) 18 047 (75.3) 5252 (75.0) 0.66
Diuretic (n ¼ 30 969) 9091 (29.4) 6449 (26.9) 2642 (37.7) ,0.0001
Calcium channel blocker (n ¼ 30 967) 8404 (27.1) 6137 (25.6) 2267 (32.4) ,0.0001
Long-acting nitrate (n ¼ 30 969) 6837 (22.1) 5028 (21.0) 1809 (25.8) ,0.0001
Ivabradine (n ¼ 30 970) 3120 (10.1) 2313 (9.6) 807 (11.5) ,0.0001
Verapamil or diltiazem (n ¼ 30 967) 1775 (5.7) 1276 (5.3) 499 (7.1) ,0.0001
Other antianginal agent (n ¼ 30 966) 4403 (14.2) 3192 (13.3) 1211 (17.3) ,0.0001
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.
Values are numbers (percentages).
aMen vs. women.
Figure 2 Events by first annual visit and odds ratios. Odds ratios and 95% confidence intervals, crude and adjusted for risk factors, age, and
baseline differences. All coronary events include: fatal myocardial infarction, non-fatal myocardial infarction, coronary revascularization
[PCI (percutaneous coronary intervention) or coronary artery bypass graft (CABG)], or unstable angina.
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significant interaction between outcomes by gender and a history
of MI or previous revascularization: women without prior MI/
revascularization being less likely than men with a similar medical
history to experience a coronary event and were less likely to
undergo revascularization (see Supplementary material online,
Table S3). Finally, we examined whether there was an interaction
between gender and age, and analysed outcomes by gender and
tertiles of age (see Supplementary material online, Table S4).
There was a significant interaction for the outcomes of fatal/non-
fatal MI, the composite of cardiovascular death and non-fatal MI
and the triple composite of cardiovascular death, non-fatal MI,
and non-fatal stroke. For all of these outcomes, women in the
younger tertile had better outcomes than men of similar age,
whereas such differences were not apparent and were even direc-
tionally opposite in older women.
Discussion
The main finding from this analysis of a large, international, con-
temporary population of outpatients with stable CAD (most of
whom had a previous MI or revascularization) is that despite sub-
stantial differences in baseline clinical characteristics and
management, the rates for cardiovascular clinical outcomes were
similar between men and women, both with and without adjust-
ment, and fewer women had a history of myocardial revasculariza-
tion at baseline. These results hold when sensitivity analyses
restrict the population studied to that with angiographic evidence
of CAD or with prior clinical events. However, it is noteworthy
that younger women (in the lower age tertile) and women
without a history of MI or revascularization actually fare better
than men with a similar profile.
These results suggest that there is no discernible excess of car-
diovascular events in women with stable CAD compared with men
and that, if anything, among younger patients or lower risk patient
groups, women actually fare better than men.
There were important baseline differences between men and
women at baseline. The women in CLARIFY were older, and
were more likely to have hypertension, diabetes, and symptomatic
angina than men, and to be receiving all types of anti-anginals,
except beta-blockers. On the other hand, they were less likely
to have had coronary angiography, revascularization, or non-
invasive testing or to be receiving statins or beta-blockers.
The data from clinical trials related to women should be inter-
preted carefully since they are often performed in highly selected
populations with under-representation of women.23 Registry
studies, particularly when performed nationwide,24,25 provide
more representative data regarding gender differences. CLARIFY,
as a large contemporary cohort of outpatients with stable CAD,
with broad geographic representation, and as such, provides infor-
mation to improve our understanding of gender issues in patients
with established but stable CAD.
The observation of gender differences in baseline characteristics
and management in this stable CAD population is in line with previ-
ous registries and cohort studies. Gender differences in risk profile
have been reported in patients with angina and ACS,5,6,26 and
women appear to be more likely than men to have a higher risk
factor burden. Coronary artery disease tends to manifest itself at
a later age in women. This may be related to a cardioprotective
effect of oestrogen,26 although this has been debated by others.27
Even though international guidelines do not dictate gender-specific
management strategies, women with stable CAD tend to have
less access to non-invasive and invasive investigations and receive
less intensive medical therapy as well as revascularization.5–7,9,14,15,28
The underlying reasons for these differences remain unclear,
though the underlying pathophysiological substrate for CAD may
be different in men and women.8,26,29,30 Women tend to have
smaller lumens and brachial artery diameters, which may influence
endothelium-dependent vasodilatation.31,32 Women are less likely
than men to undergo angiography (as was seen in CLARIFY during
the 1-year follow-up) and, if they do, have lower rates of obstruct-
ive CAD,6,30,33 which account in part for the lower rates of revas-
cularization in women in CLARIFY, and they also have less severe
disease, with lower rates of multivessel disease.34 There are higher
rates of microvascular disease in women.26,35 Older women have
lower plaque burden than men, smaller atheroma volume, and
are less likely to have plaque calcification and rupture.26,30,32
However, in younger women, the prevalence of coronary lesions
appears similar in women compared with men, although plaque
burden may be lower.36 On the other hand, the gender differences
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Table 3 Outcomes in selected patient subsets
Event No. of
events
ORa (95% CI) P-value
Patients with MI or revascularization at baseline (n ¼ 28 026)
All-cause death 414 0.97 (0.77–1.23) 0.80
Fatal or non-fatal MI 268 0.82 (0.60–1.12) 0.20
CV death or non-fatal
MI
389 0.93 (0.72–1.19) 0.54
CV death/non-fatal MI/
non-fatal stroke
482 0.98 (0.78–1.22) 0.83
All coronary eventsb 1596 1.04 (0.92–1.18) 0.52
Unstable angina 1067 1.14 (0.99, 1.32) 0.08
Revascularization
(PCI or CABG)
677 0.86 (0.71–1.05) 0.13
Patients with angiographic evidence of CAD (≥1 vessel disease)
(n ¼ 25 314)
All-cause death 327 0.93 (0.71–1.22) 0.61
Fatal or non-fatal MI 229 0.90 (0.64–1.24) 0.49
CV death or non-fatal
MI
315 0.95 (0.72–1.25) 0.74
CV death/non-fatal MI/
non-fatal stroke
387 0.98 (0.76–1.26) 0.87
All coronary eventsb 1367 1.06 (0.92–1.21) 0.42
Unstable angina 887 1.14 (0.97–1.34) 0.11
Revascularization (PCI
or CABG)
635 0.84 (0.68–1.03) 0.10
CAD, coronary artery disease; CV, cardiovascular.
aOdds ratio for women vs. men and 95% confidence interval adjusted for risk
factors, age, and baseline differences.
bFatal myocardial infarction, non-fatal myocardial infarction, coronary
revascularization [PCI (percutaneous coronary intervention) or coronary artery
bypass graft (CABG)], or unstable angina.
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may also be related to physician and patient behaviour; for
example, women are often perceived by physicians to be at
lower cardiovascular risk than men and appear to be underdiag-
nosed—possibly because of more frequent atypical presenta-
tion37—undergo far less frequent non-invasive or invasive testing,
and are referred less frequently for revascularization than men
(as indeed seen in CLARIFY). They may also be less willing to
undergo invasive procedures, which may reduce the level of care
they receive.6 Clearly, concerted efforts are needed to modify
both physician and patient behaviours by increasing awareness of
the prevalence of CAD in women (as done through mass media
campaigns such as the ‘Women at Heart’ initiative by the European
Society of Cardiology or the ‘Go Red for Women’ campaign of the
American Heart Association), by educating physicians to the differ-
ences in biology, and clinical presentation of women with CAD
compared with men, the need for more active testing and referral
of women with suspected or proven heart disease and the need
for uniform application of guidelines and evidence to the manage-
ment of women and men with CAD.38
Some6,9 but not all11 studies have reported gender differences in
outcomes in stable CAD patients with angina. In ACS, the evidence
is somewhat conflicting, with observations of gender differ-
ences5,7,8,39,40 or no gender difference.12– 14 However, many
studies suggest that women have worse outcomes following
ACS, even after adjustment for age. This may be partly due to
the lower use of revascularization in women.41 In contrast, data
in patients with stable CAD and hypertension indicated that
despite higher blood pressures and more comorbidities, women
had a lower rate of cardiovascular events (death, MI, or
stroke).42 Across all types of CAD subsets, the use of revascular-
ization is generally lower in women than in men in the literature, as
was seen in CLARIFY.6,39 It remains possible that while women
with CAD tend to have less severe coronary obstructive disease
than men31—and therefore possibly a better outcome—this may
be balanced by the more severe outcomes of non-obstructive
CAD among women.43 The known gender bias in diagnosis and
access to diagnostic interventions, as found in CLARIFY and else-
where,9,14,44,45 is likely to modify long-term prognosis. Although
the present study did not explore appropriateness for interven-
tions, there are no data to support reduced efficacy of optimal
medical therapy or revascularization in women.45
While we found no overall gender difference in outcomes in
stable CAD, this may actually reflect offsetting trends by age:
there was an interaction between age and gender, with younger
women having better outcomes than men in the same age class,
whereas this was not the case for the middle or higher age tertiles.
Differences between studies may also be related to the role and
prognostic impact of percutaneous interventions: in ACS, where
the use of PCI is associated with established clinical benefit, the
lower rate of use seen in women may impact outcomes,
whereas in patients with stable CAD, where the benefits of
routine revascularization are less established,46,47 the major differ-
ence between men and women in the use of PCI would not be
expected to impact outcomes.
Finally, with improved outcomes related to broader use of ef-
fective evidence-based secondary prevention therapies, such as
statins, renin–angiotensin system inhibitors, and antiplatelet
agents, the potential to demonstrate differences between
genders diminishes. Therefore, a more contemporary study such
as CLARIFY may not identify differences seen a decade ago in
large trials or registries.
Our study is not without limitations.21 First, the purely observa-
tional nature of our study prevents any causality inference, because
even though we attempted to adjust for multiple measured poten-
tial confounders, it is not possible to exclude confounding by un-
measured variables. Secondly, despite the large size of the
CLARIFY population, there were no patients enrolled from the
USA, though it did include .2500 patients from Canada,
Mexico, and Central America. Thirdly, physician and patient partici-
pation in the CLARIFY registry was on a voluntary basis, and as
such, is not as representative as a population-based sample.
However, every effort was made to maximize the representative-
ness of the physician and patient samples in each country. The 23%
rate of representation of women in CLARIFY may still be lower
than in routine clinical practice. The cohort enrolled patients
with established CAD, but who survived the first episode and
this may underestimate gender differences in mortality related to
a first episode of CAD. One of the selection criteria was the pres-
ence of chest pain with evidence of myocardial ischaemia, yet ex-
ercise electrocardiographic changes in women are more often
‘false positives’ than in men, which may have skewed enrolment
of women towards lower risk. One cannot exclude that enrolment
based in part on prior revascularization or angiographic demon-
stration of obstructive CAD may have minimized the participation
of those women who tend to undergo less frequently revascular-
ization and have more frequently non-obstructive CAD, in whom
outcomes may differ from women with the more typical form of
CAD.48 It also may explain the relatively low proportion of
women in the registry, as women are less likely than men to
achieve eligibility based on prior angiography or revascularization.
Another important consideration is that this analysis was not a
non-inferiority study and thus was not pre-specified to rule out a
given difference in event rates between men and women. Despite
the very large size of the trial, event rates are somewhat low and
the CIs for ORs by gender show that, even though point estimates
for event rates are below 1, one cannot rule out an actual increase
in risk of cardiovascular event rates of 15% (Figure 2). Finally,
2.8% of the patients were lost to follow-up, and 3.6% of the
patients had incomplete data at the time of database lock and
were not included in the analyses, although this is unlikely to
change the results dramatically.
In summary, there were important differences in baseline char-
acteristics and in risk between men and women, and fewer women
underwent revascularization. Nevertheless, we found similar crude
and adjusted rates of mortality and cardiovascular events in men
and women with stable CAD. Longer follow-up of this population
should provide further insights into gender issues in stable CAD.
Further research is also needed to devise strategies to minimize
bias in the management and treatment of women.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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